Enanta Pharmaceuticals, Inc. (ENTA)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 15.1M | 18.6M | 17.2M | 14.4M |
| Operating Income | (18.4M) | (11.3M) | (11.9M) | (17.2M) |
| Net Income | (18.7M) | (11.9M) | (13.1M) | (19.5M) |
| Diluted EPS | $-0.87 | $-0.42 | $-0.45 | $-0.67 |
Annual Financials
| Metric | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | 86.2M | 79.2M | 67.6M | 65.3M |
| Operating Income | (123.8M) | (137.2M) | (121.7M) | (85.3M) |
| Net Income | (121.8M) | (133.8M) | (116.0M) | (81.9M) |
| Diluted EPS | $-5.91 | $-6.38 | $-5.48 | $-3.84 |